Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682826 | 0.87 | ESR1 (0.43) | PDE7APIK3CD | |
| SCHEMBL17678230 | 0.87 | ESR1 (0.40) | PDE7APIK3CD | |
| SCHEMBL28410346 | 0.83 | PIK3CD (0.47) | PDE7APIK3CDCFTR | |
| SCHEMBL30619300 | 0.83 | PIK3CD (0.47) | PDE7APIK3CDCFTR | |
| SCHEMBL13135674 | 0.80 | SMN1; SMN2 (0.46) | GAASMN1; SMN2ALOX15KHKPOLB | |
| SCHEMBL25335464 | 0.78 | HRH4 (0.41) | GAASMN1; SMN2ALOX15HTTMEN1 | |
| SCHEMBL15837036 | 0.76 | OPRM1 (0.40) | GAASMN1; SMN2HTTMEN1POLB | |
| SCHEMBL31261977 | 0.76 | PDGFRA (0.37) | GAAHTTPIK3CD | |
| SCHEMBL29190627 | 0.75 | GAA (0.49) | GAASMN1; SMN2ALOX15PDE7AP2RX7 | |
| SCHEMBL30833690 | 0.75 | GAA (0.49) | GAASMN1; SMN2ALOX15PDE7AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | GAA 1186/4885SMN1; SMN2 1175/4885ALOX15 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.